AstraZeneca (NASDAQ: $AZN) posted its Q1 2025 earnings on April 29. The stock trades at $70.13. Revenue for the quarter rose 10% year-over-year to $13.59 billion. The company saw growth across all regions and segments. Oncology and BioPharmaceuticals led revenue gains. Oncology sales grew 13%, while BioPharmaceuticals also expanded in double digits.
Core operating profit rose 12%. Core earnings per share (EPS) reached $2.49, marking a 21% increase. The core tax rate was 16% for Q1. AstraZeneca maintained full-year guidance. It expects high single-digit revenue growth and low double-digit growth in core EPS.
CEO Pascal Soriot highlighted five positive Phase III trial readouts. These include Enhertu’s DESTINY-Breast09 and Imfinzi’s MATTERHORN. Camizestrant’s SERENA-6 trial also saw success. The MATTERHORN and SERENA-6 trials will feature at ASCO 2025.
AstraZeneca reaffirmed its plan to hit $80 billion in revenue by 2030. The firm operates 11 manufacturing sites in the U.S. and will expand investments in U.S. R&D. Two large R&D centers are located in Maryland and Massachusetts. It plans to invest $3.5 billion in the U.S. by the end of 2026.
Sales in the U.S. account for about 40% of the company’s total. Growth remained solid despite tariff threats from the Trump administration. AstraZeneca said it remains committed to U.S. expansion. However, the company is facing scrutiny in China over unpaid import taxes. Authorities in Shenzhen allege $1.6 million in unpaid taxes. AstraZeneca may face a fine between one and five times that amount.
The company reported 13 major approvals since its last earnings update. It is now in what it calls a “catalyst-rich” period. Management expects stable exchange rates to have only a minor impact on full-year results.
Technical Analysis
AstraZeneca shares have rebounded from a recent low of $62. The stock is trading at $70.13. A bounce from long-term support between $61 and $63 sparked the move. The price is now approaching major resistance between $75 and $77. This range held as support and resistance several times in 2023, early 2024, and 2025 as well.
Volume increased during the bounce, confirming demand. The 50-day moving average is climbing. It sits at $72.66. The 100-day and 200-day averages are $70.42 and $73.69, respectively. Price now trades between these key levels. RSI stands at 54.50, with momentum still rising. MACD also supports bullish momentum above the signal line.
A potential path includes a short-term pullback near resistance. If price holds above $70, it could break past $78. The projected upside target is $87.68, which matches the stock’s prior high from late 2024.
Is Now The Time To Buy AstraZeneca?
AstraZeneca has delivered strong financial and pipeline growth. Sales increased across all major segments. Oncology drugs like Enhertu and Imfinzi posted strong numbers. The company also saw positive developments in China and the U.S.
Core EPS rose 21%. Management kept full-year guidance unchanged. With new trial successes and regulatory approvals, AstraZeneca expects to grow further. Technical indicators show a recovery in motion. Price action and volume confirm strong interest.
However, the price is approaching a key resistance zone. Investors may watch for a breakout or a retest of lower support. AstraZeneca’s long-term target of $80 billion in revenue remains in play. The company also offers a forward dividend yield of 2.22%.
Current stock price levels suggest caution near resistance. But technical and fundamental trends support the stock’s growth outlook.
Click Here For Updates on AZN – It’s FREE to Sign Up for Text Message Notifications!
Disclaimer: This website provides information about cryptocurrency and stock market investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for educational and informational purposes only. The owner of this website is not a registered investment advisor and does not offer investment advice. You, the reader / viewer, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.
